{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:42:38Z","timestamp":1790448158382,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.22874","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T15:01:22Z","timestamp":1603983682000},"page":"e2022874","source":"Crossref","is-referenced-by-count":79,"title":["Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States"],"prefix":"10.1001","volume":"3","author":[{"given":"Gregory F.","family":"Guzauskas","sequence":"first","affiliation":[{"name":"The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Garbett","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Institute for Public Health Genetics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadley S.","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Hassen","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Behavioral Sciences, Georgia State University, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Graves","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh F.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle"},{"name":"Institute for Public Health Genetics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"23","key":"zoi200763r1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"zoi200763r2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"zoi200763r4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.6004\/jnccn.2016.0018","article-title":"Genetic\/familial high-risk assessment: breast and ovarian, version 2.2015.","volume":"14","author":"Daly","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"31","key":"zoi200763r5","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.","volume":"33","author":"Robson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"39","key":"zoi200763r6","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"zoi200763r7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing\u2013based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants.","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi200763r8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.","volume":"312","author":"King","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"zoi200763r10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement.","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"zoi200763r12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"issue":"7","key":"zoi200763r13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women.","volume":"110","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6319","key":"zoi200763r18","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf6814","article-title":"Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR Study.","volume":"354","author":"Dewey","year":"2016","journal-title":"Science"},{"issue":"15","key":"zoi200763r19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients.","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"zoi200763r20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41525-018-0046-7","article-title":"Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices.","volume":"3","author":"Toland","year":"2018","journal-title":"NPJ Genom Med"},{"issue":"1","key":"zoi200763r21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing.","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200763r22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","article-title":"MRI breast screening in high-risk women: cancer detection and survival analysis.","volume":"145","author":"Evans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"zoi200763r23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer.","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"zoi200763r24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life\u2013related utilities for health states relevant to ovarian cancer diagnosis and treatment.","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"zoi200763r25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2017.01.006","article-title":"A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer.","volume":"20","author":"Li","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"zoi200763r26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-1536","article-title":"Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies.","volume":"164","author":"Mandelblatt","year":"2016","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi200763r27","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer.","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi200763r29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","article-title":"Delivery of cascade screening for hereditary conditions: a scoping review of the literature.","volume":"37","author":"Roberts","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi200763r30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10897-016-9995-0","article-title":"Psychosocial and clinical factors associated with family communication of cancer genetic test results among women diagnosed with breast cancer at a young age.","volume":"26","author":"Elrick","year":"2017","journal-title":"J Genet Couns"},{"issue":"2","key":"zoi200763r31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi200763r32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.","volume":"7","author":"Domchek","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200763r33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jpm10010007","article-title":"Healthcare utilization and costs after receiving a positive BRCA1\/2 result from a genomic screening program.","volume":"10","author":"Hao","year":"2020","journal-title":"J Pers Med"},{"issue":"4","key":"zoi200763r34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jval.2017.01.004","article-title":"A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer.","volume":"20","author":"Eccleston","year":"2017","journal-title":"Value Health"},{"issue":"3","key":"zoi200763r35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","article-title":"Comparative effectiveness of screening and prevention strategies among BRCA1\/2\u2013affected mutation carriers.","volume":"125","author":"Grann","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"zoi200763r37","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1038\/s41436-019-0580-4","article-title":"Cost-effectiveness of population genomic screening.","volume":"21","author":"Veenstra","year":"2019","journal-title":"Genet Med"},{"issue":"12","key":"zoi200763r38","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41436-019-0581-3","article-title":"Response to Veenstra et al.","volume":"21","author":"Lacaze","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"zoi200763r39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11864-016-0417-1","article-title":"Health care disparities in hereditary ovarian cancer: are we reaching the underserved population?","volume":"17","author":"Randall","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"13","key":"zoi200763r40","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.v123.13","article-title":"Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.","volume":"123","author":"Cragun","year":"2017","journal-title":"Cancer"},{"key":"zoi200763r14","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001","volume-title":"Cost-effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"key":"zoi200763r36","author":"Guzauskas"},{"key":"zoi200763r3","unstructured":"US Preventive Services Task Force. Breast cancer: medication use to reduce risk. Published September 3, 2019. Accessed March 1, 2020. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/breast-cancer-medications-for-risk-reduction"},{"key":"zoi200763r9","unstructured":"Centers for Disease Control and Prevention. Tier 1 genomics applications and their importance to public health. Updated March 6, 2014. Accessed December 27, 2019. https:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/tier1.htm"},{"key":"zoi200763r11","unstructured":"United States Census Bureau. 2018: ACS 1-year estimates subject tables. Accessed December 27, 2019. https:\/\/data.census.gov\/cedsci\/table"},{"key":"zoi200763r15","unstructured":"Centers for Disease Control and Prevention. United States life tables, 2017. Natl Vital Stat Rep. 2017;68(7):1-66. Published June 24, 2019. Accessed December 27, 2019. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_07-508.pdf"},{"key":"zoi200763r16","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. Accessed September 19, 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html?"},{"key":"zoi200763r17","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Accessed September 19, 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"zoi200763r28","unstructured":"Color Genomics Inc. Your tests. Accessed March 1, 2020. https:\/\/home.color.com\/purchase\/ordering-physician?sku=combo%203"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2772341\/guzauskas_2020_oi_200763_1603374715.56729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T15:01:53Z","timestamp":1603983713000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2772341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.22874","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]}}}